Skip to main content

Select Drug Profiles

Original Research

Atypical Antipsychotics and Metabolic Syndrome in Patients with Schizophrenia: Risk Factors, Monitoring, and Healthcare Implications

Henry J. Riordan, PhD, Paola Antonini, MD, PhD, Michael F. Murphy, MD, PhD

Stakeholder Perspective

The Complexities of Treating Mental Illness

by Atheer A. Kaddis, PharmD

Original Research

Current Therapies and Emerging Drugs in the Pipeline for Type 2 Diabetes

Karmella T. Thomas, BS, RD, Katie B. Lyons, MS II, Loida D. Nguyen, PharmD, BCPS, Raymond A. Plodkowski, MD, Quang T. Nguyen, DO, FACE, FTOS

Stakeholder Perspective

New Therapies with Novel Mechanisms of Action Are Urgently Needed for Type 2 Diabetes

by James V. Felicetta, MD

Original Research

Lipid Management in Patients with Type 2 Diabetes

Marsha J. Daniel, PharmD, cPh, CDE

Stakeholder Perspective

The Time Is Now to Promote Aggressive Lipid Management to Prevent Macrovascular Complications in Patients with Type 2 Diabetes

by Gary M. Owens, MD

Can Episode Payments Reduce Cost and Maintain Quality Cancer Care?

Caroline Helwick

Economic Recession Affects Rates of Cancer Incidence and Treatment

Value of Targeted Therapies in Patients Lacking a Molecular Target Questioned

Caroline Helwick

Most End-of-Life Costs for Patients with Cancer Are Not Drug-Related

Bankruptcy Rates Markedly Greater for Cancer Survivors

Inappropriate Antineoplastic Agents Use for Metastatic Cancer Costs Insurers Millions

Multiple Myeloma, Oncology

Multiple Myeloma Treatments Are Moving Rapidly from Bench to Bedside

Page 214 of 244
Results 2131 - 2140 of 2438